Literature DB >> 3101843

Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis.

G A Ellard, M J Humphries, M Gabriel, R Teoh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3101843      PMCID： PMC1245297          DOI： 10.1136/bmj.294.6567.284

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  5 in total

1.  The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.

Authors:  G A Ellard; D R Ellard; B W Allen; D J Girling; A J Nunn; S K Teo; T H Tan; H K Ng; S L Chan
Journal:  Am Rev Respir Dis       Date:  1986-06

2.  Pyrazinamide and other drugs in tuberculous meningitis.

Authors:  R Forgan-Smith; G A Ellard; D Newton; D A Mitchison
Journal:  Lancet       Date:  1973-08-18       Impact factor: 79.321

3.  The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis.

Authors:  D J Girling
Journal:  Tubercle       Date:  1984-03

4.  [Comparison of the therapeutic efficacy of the so-called heavy and lightened antitubercular regimens].

Authors:  R Bretton; C Monthaneix; C Coulibaly; G Bretton; D Rey
Journal:  Bull Int Union Tuberc       Date:  1985 Mar-Jun

5.  Dosage of antituberculous drugs in obese patients.

Authors:  P J Geiseler; R D Manis; M S Maddux
Journal:  Am Rev Respir Dis       Date:  1985-06
  5 in total
  15 in total

1.  The management of tuberculous meningitis.

Authors:  M Humphries
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

2.  Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.

Authors:  Maria C Kjellsson; Laura E Via; Anne Goh; Danielle Weiner; Kang Min Low; Steven Kern; Goonaseelan Pillai; Clifton E Barry; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

Review 3.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis.

Authors:  Daniel T Hoagland; Jiuyu Liu; Robin B Lee; Richard E Lee
Journal:  Adv Drug Deliv Rev       Date:  2016-05-02       Impact factor: 15.470

4.  Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

5.  Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

6.  Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study.

Authors:  Christopher Vinnard; Carla A Winston; E Paul Wileyto; Rob Roy Macgregor; Gregory P Bisson
Journal:  BMJ       Date:  2010-09-06

Review 7.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

Review 8.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

Review 9.  Central nervous system tuberculosis: pathogenesis and clinical aspects.

Authors:  R Bryan Rock; Michael Olin; Cristina A Baker; Thomas W Molitor; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

10.  The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis.

Authors:  P Phuapradit; K Supmonchai; S Kaojarern; C Mokkhavesa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-01       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.